Previous Close | 24.78 |
Open | 24.61 |
Bid | 24.83 x 100 |
Ask | 25.19 x 100 |
Day's Range | 24.38 - 25.56 |
52 Week Range | 9.44 - 36.25 |
Volume | |
Avg. Volume | 1,231,741 |
Market Cap | 1.28B |
Beta (5Y Monthly) | 2.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.58 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 52.20 |
On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing.
Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), has sold 5,833 shares of the company on March 27, 2024, according to a recent SEC filing.
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate approved CF modulator therapies AEROW clinical trial Phase 2 Expansion Cohort dose selection and initiation expected in Q2 2024, with pivotal trial initiation anticipated in H2 2025Initial GMP-ready suspe